Efecto de las estatinas en los niveles de LP(A) de adultos.

Abstract

Atherosclerotic cardiovascular disease is a leading cause of death worldwide, with lipid disorders being a key factor in its development. Lipoprotein(a) has been recognized as an independent risk factor for cardiovascular disease. Given the importance of statins in the treatment of dyslipidemia, it is crucial to investigate their relationship with lipoprotein(a). Objective: To determine if there is an association between statin use and the reduction of lipoprotein(a) levels in adults. Method: A search was conducted in PubMed and Cochrane Library for randomized clinical trials published between 2013 and 2023. Studies conducted in adults using statins as the only lipid-lowering agent were included. The PRISMA 2020 statement guidelines were followed for article selection and retrieval. Scientific quality was assessed using the CASPe questionnaire and the RoB 2 tool for risk of bias. Results: Six clinical trials were included (n= 17203). The reduction of lipoprotein(a) through statin use compared to placebo did not show significant differences in most included studies. However, rosuvastatin treatment was associated with a certain increase in these levels. Additionally, an inverse association between lipoprotein(a) levels and cases of diabetes was observed. Conclusions: Statins do not have a significant effect on reducing lipoprotein(a) levels.